Sarepta asks FDA to approve first gene therapy for Duchenne muscular dystrophy

Sarepta asks FDA to approve first gene therapy for Duchenne muscular dystrophy

Submitted by admin on September 29, 2022 - 7:38pm
Source: 
BioPharma Dive
News Tags: 
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
gene therapy
SRP-9001
Headline: 
Sarepta asks FDA to approve first gene therapy for Duchenne muscular dystrophy
snippet: 

Sarepta Therapeutics has asked the Food and Drug Administration to approve its gene therapy for Duchenne muscular dystrophy under accelerated review, the company said Thursday.

Do Not Allow Advertisers to Use My Personal information